Waters Corporation Merges with BD Biosciences & Diagnostic Solutions in $18.8B Reverse Morris Trust: Liquid Chromatography, Flow Cytometry, Mass Spectrometry, and the $40B Life Science Tools Market

Deal at a Glance

On July 14, 2025, Waters Corporation (NYSE: WAT) and Becton, Dickinson and Company (NYSE: BDX) announced a definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters in a tax-efficient Reverse Morris Trust transaction. The deal closed on February 9, 2026, with the BD Biosciences & Diagnostic Solutions business valued at $18.8 billion based on Waters' closing stock price on February 6, 2026.

This is one of the largest life sciences transactions in history and the most significant reshaping of the analytical instruments and diagnostics tools market since Thermo Fisher's acquisitions of Patheon and PPD. For medical device and IVD manufacturers, the deal consolidates two major suppliers of analytical platforms, flow cytometers, and diagnostic technologies that are essential to product development, quality control, and regulatory submissions.

Deal Structure and Timeline

The transaction was structured as a Reverse Morris Trust (RMT), a tax-efficient mechanism that allows a parent company to divest a subsidiary while avoiding the heavy tax burden of a direct sale. Here is how it worked:

1. Spin-off: BD spun off its Biosciences & Diagnostic Solutions business into a separate entity ("SpinCo")
2. Merger: SpinCo merged with a wholly owned subsidiary of Waters, becoming a wholly owned subsidiary of Waters
3. Ownership split: Existing Waters shareholders received 60.8% of the combined company; BD shareholders received 39.2%
4. Cash distribution: BD received $4 billion in cash prior to the combination

This structure allowed BD to monetize its Biosciences & Diagnostic Solutions business without triggering a taxable event for BD or its shareholders — a critical consideration given the size of the transaction.

Key Timeline

• July 14, 2025: Definitive agreement announced
• January 27, 2026: BD sets record date (February 5, 2026) for the spin-off
• February 5, 2026: Record date for BD shareholders entitled to receive Waters shares
• February 6, 2026: BD shares begin trading with "due bills" on NYSE
• February 9, 2026: Transaction closes; combination becomes effective
• February 10, 2026: BD shares trade "ex-distribution" (without Waters entitlement)

Leadership and Governance

Udit Batra continues as president and CEO of the combined Waters Corporation. Dr. Flemming Ornskov, who served as chair of Waters, emphasized the strategic fit: "Combining with BD's Biosciences & Diagnostic Solutions business is an excellent strategic fit with complementary strengths." Claire M. Fraser, Ph.D., was appointed to the Waters Board of Directors, expanding it to 11 members.

BD's Strategic Rationale: Portfolio Focus

For BD, the transaction represents the culmination of a multi-year portfolio optimization strategy. CEO Tom Polen described the deal as part of BD's "Excellence Unleashed" strategy — strengthening the company's commercial engine, leading with differentiated innovation, and delivering with exceptional quality.

What BD Retains

Following the transaction, BD is a more focused medical technology company centered on:

• Medication Delivery Solutions: Syringes, needles, IV catheters, infusion systems
• Pharmaceutical Systems: Prefillable syringes, drug delivery devices
• Interventional Solutions: Catheters, guidewires, vascular access devices
• Surgical Solutions: Wound management, surgical instrumentation
• Diagnostic Solutions (remaining): Point-of-care testing (not included in the spin-off)

BD expects to use $2 billion of the $4 billion cash proceeds to repurchase BD common shares through an accelerated share buyback program, with the remainder directed toward debt reduction and general corporate purposes.

What BD Divested

The Biosciences & Diagnostic Solutions business that went to Waters included:

• Flow Cytometry: BD FACSymphony, FACSMelody, FACSCelesta, FACSDual, and research-use-only (RUO) cell analysis platforms — one of the largest flow cytometry portfolios in the world
• Biologics Discovery: BD's entire biologics and protein analysis franchise
• Diagnostic Instrumentation: Clinical diagnostic instruments and systems used in hospital and reference laboratories
• Reagents and Consumables: The full portfolio of reagents, kits, and consumables for cell analysis and diagnostics
• Genomics Solutions: Select genomic analysis platforms and services

The business generated significant revenue with a highly recurring consumables model — a key attraction for Waters.

Waters' Strategic Rationale: Doubling the Addressable Market

For Waters Corporation, the deal is transformational. Prior to the combination, Waters was primarily known as a leading manufacturer of liquid chromatography (LC) and mass spectrometry (MS) systems used in pharmaceutical development, food safety testing, and environmental analysis. The BD Biosciences combination fundamentally changes the company's market position.

Doubling the TAM

The combined company's total addressable market approximately doubles to $40 billion, spanning:

• Liquid Chromatography (LC): Waters' flagship platform
• Mass Spectrometry (MS): Waters' high-resolution and tandem MS systems
• Flow Cytometry: BD's world-leading cell analysis platforms
• Diagnostic Solutions: Clinical diagnostic instruments and reagents
• Biologics Quality Control: Combined LC/MS + flow cytometry capabilities for biotherapeutic characterization

The Recurring Revenue Thesis

A central strategic argument for the deal is the recurring revenue profile. The combined company expects over 70% of revenue to be recurring annually, driven by:

• Consumables, reagents, and kits (high-margin, repeat-purchase products)
• Service contracts and instrument maintenance agreements
• Software licenses and informatics subscriptions
• Over half of instrument revenue recurring within a typical 5-to-10-year replacement cycle

This recurring revenue model is highly valued by investors because it provides revenue visibility, margin stability, and reduced cyclicality compared to one-time instrument sales.

Technology Portfolio: What the Combined Company Offers

Liquid Chromatography and Mass Spectrometry (Waters)

Waters brings its industry-leading LC and MS platforms, which are essential tools in pharmaceutical development, bioprocessing quality control, food safety, and environmental testing. Key platforms include:

• ACQUITY UPLC Systems: Ultra-performance liquid chromatography for high-resolution separation
• Xevo Mass Spectrometers: Tandem and high-resolution MS for identification and quantification
• BioAccord Systems: Biopharmaceutical characterization with integrated LC-MS
• Waters Connect Software: Cloud-enabled informatics platform for data management

For medical device and IVD manufacturers, Waters' LC-MS platforms are critical for extractables and leachables (E&L) testing of device materials, biocompatibility assessments, and analytical method development for regulatory submissions.

Flow Cytometry and Cell Analysis (BD Biosciences)

BD's Biosciences division brings one of the world's most comprehensive flow cytometry portfolios:

• BD FACSymphony: High-parameter spectral flow cytometry for deep immunophenotyping
• BD FACSMelody: Cell sorting platform for research applications
• BD FACSCelesta: High-throughput cell analyzer
• BD Rhapsody: Single-cell multiomics platform
• BD Research Reagents: Antibodies, kits, and reagents for cell analysis

For IVD manufacturers, flow cytometry is essential for companion diagnostic development, immunophenotyping assays, and quality control of cell-based therapies.

The Biologics Quality Control Nexus

The combination creates a unique capability in biotherapeutic and biologics quality control. Waters' strength in LC/MS-based characterization of protein structure, post-translational modifications, and aggregation complements BD's cell-based assays, potency testing, and flow cytometry-based analytics. Together, the combined company can offer end-to-end analytical workflows for:

• Monoclonal antibody characterization
• Cell and gene therapy product testing
• Vaccine quality control
• Biosimilarity assessment
• Host cell protein impurity analysis

Synergy Projections and Financial Outlook

The companies have provided detailed synergy projections:

Cost Synergy Drivers

Cost synergies are expected primarily from:

• Manufacturing optimization and consolidation
• Supply chain rationalization
• SG&A efficiencies (overlapping functions, facilities)
• Procurement leverage on shared components and raw materials

The companies committed to maintaining strong R&D and commercial investment even as cost synergies are realized.

Revenue Synergy Drivers

Revenue synergies are expected from cross-selling opportunities:

• Selling Waters LC/MS platforms into BD's installed base of clinical laboratories
• Bundling BD flow cytometry consumables with Waters informatics solutions
• Offering integrated analytical workflow solutions that combine both portfolios
• Expanding into adjacent end markets (e.g., cell and gene therapy manufacturing QC)

Financial Targets

The combined company has set ambitious targets for 2030:

• Revenue: ~$9 billion
• Adjusted EBITDA: ~$3.3 billion
• Recurring Revenue: >70% of total

Implications for Medical Device and IVD Manufacturers

For IVD and Diagnostic Kit Manufacturers

The Waters-BD combination has direct implications for IVD manufacturers who rely on analytical instruments for:

• Assay development and validation: Waters LC/MS and BD flow cytometry platforms are used in IVD assay development
• Calibrator and control manufacturing: Traceability to reference methods often requires LC/MS analysis
• Raw material qualification: Biological raw materials (antibodies, antigens) are characterized using flow cytometry and LC/MS
• Manufacturing QC release testing: Finished IVD product release testing often uses these analytical platforms

The consolidation of two major analytical instrument suppliers into one company could affect pricing, service terms, and technology roadmap decisions for IVD manufacturers. Companies should evaluate their instrument vendor diversification strategy and consider whether to maintain multi-vendor analytical capabilities.

For Medical Device Manufacturers

Medical device manufacturers use Waters and BD platforms for:

• Extractables and leachables testing: LC/MS analysis of chemical compounds migrating from device materials (ISO 10993-18)
• Material characterization: Polymer and resin analysis for medical-grade materials
• Cleanliness and bioburden testing: Flow cytometry-based microbial analysis
• Sterilization validation: Chemical analysis of sterilization residues

The deal means that two key analytical instrument vendors are now under one corporate umbrella, which could streamline integrated analytical workflows but also concentrates purchasing leverage.

For Regulatory Submissions

From a regulatory perspective, the combined company's platforms generate data that supports:

• FDA 510(k) submissions with analytical validation data
• EU IVDR performance evaluation reports with analytical performance characteristics
• ISO 13485 quality management system analytical instrument qualification
• ASTM F1980 accelerated aging studies for shelf-life testing

Competitive Landscape

The Waters-BD combination reshapes the life science tools competitive landscape:

While the combined Waters is still smaller than Thermo Fisher and Danaher in absolute terms, its focused position in regulated, high-volume testing — with a high recurring revenue mix — differentiates it from broader diversified competitors.

What This Means for the Industry

1. Continued Portfolio Reshaping in MedTech and Life Sciences

The Waters-BD deal is part of a broader trend of portfolio reshaping in the healthcare and life sciences industry. BD's spin-off follows similar moves by:

• J&J: Exploring sale or spinoff of DePuy Synthes orthopedics ($20B+ potential value; Bloomberg, February 2026)
• Solventum: Spun off from 3M (2024), subsequently divested purification and filtration
• Medtronic: Exploring divestitures of non-core businesses
• GE HealthCare: Completed spin-off from GE (2023)

Companies are increasingly streamlining their portfolios to concentrate capital on differentiated technologies and high-growth segments. For BD, the spin-off allows sharper focus on its core medical device and medication delivery businesses while returning capital to shareholders.

2. The Rise of the Analytical-Diagnostics Hybrid

The Waters-BD combination creates a new type of company: an analytical instruments powerhouse with deep diagnostics capabilities. This positions the combined entity to capture value across the full spectrum from drug discovery through clinical diagnostics — a strategy that Thermo Fisher, Danaher, and Agilent are also pursuing.

3. Implications for Instrument Procurement

Medical device and IVD manufacturers should consider the following:

• Single vs. multi-vendor strategy: With two major analytical instrument suppliers now combined, evaluate whether your quality control laboratory needs diversification
• Service contract consolidation: The combined company may offer integrated service agreements across LC/MS and flow cytometry platforms, potentially offering cost savings
• Technology roadmap alignment: Ensure your analytical instrument roadmap aligns with the combined company's technology investments
• Vendor qualification updates: Update your approved supplier lists and vendor qualification records to reflect the corporate change

Key Takeaways

1. Deal size and significance: The $18.8 billion Waters-BD Biosciences combination is one of the largest life science tools transactions in history, creating a focused analytical instruments and diagnostics leader.

2. BD portfolio optimization: The spin-off is part of BD's broader "Excellence Unleashed" strategy to focus on its core medical technology businesses while returning $4 billion in capital.

3. Recurring revenue model: Over 70% of the combined company's revenue is recurring, driven by consumables, service contracts, and software — a highly attractive financial profile.

4. Industry consolidation: The deal reflects continued consolidation and portfolio reshaping across the life science tools and medical technology sectors.

5. Practical implications: IVD and medical device manufacturers should assess how the consolidation of two major analytical instrument suppliers affects their procurement, quality control, and regulatory submission strategies.

Last updated: May 29, 2026